Abstract 2948: A spatial-trapping mechanism of RAF by RAF/MEK glue enables full-dose combination with a pan-RAF inhibitor and drives potent, RAS-mutant tumor-selective MAPK and growth inhibition.

作者
Bijaya Gaire,Ana Orive-Ramos,Christos Adamopoulos,Beau Baars,Mathieu Desaunay,Evangelia Matenoglou,Silvia Coma,Nayeli Gutierrez-Trejo,Kevin Mohammed,Stuart A. Aaronson,Jian Jun Jin,Tiphaine C. Martin,Ernesto Guccione,Evripidis Gavathiotis,Jonathan A. Pachter,Poulikos I. Poulikakos
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:86 (7_Supplement): 2948-2948 被引量:1
标识
DOI:10.1158/1538-7445.am2026-2948
摘要

Abstract The therapeutic benefits of MAPK pathway inhibitors depend on achieving more potent pathway inhibition in tumors over normal tissues, maintaining a broad therapeutic index. In BRAF-mutant cancers, selective BRAF inhibitors (BRAFi) achieve this balance, and their combination with MEK inhibitors (MEKi) at full doses resulted in significant clinical benefit. In contrast, next-generation Type 2 dimeric RAF, also known as pan-RAF inhibitors (pan-RAFi), which target wild-type BRAF and CRAF and demonstrate single-agent activity in RAS-mutant (RAS-MUT) tumors, have failed to achieve comparable therapeutic impact in combination with MEKi, owing to toxicity-driven dose reductions that constrain clinical efficacy. In preclinical and clinical studies, these combinations have reached a therapeutic ceiling, yielding predominantly stable disease and only rare tumor regressions. We show that dose-limiting toxicity in pan-RAFi + MEKi combinations stems from relief of negative feedback by MEK inhibition, which amplifies RAF activation and pan-RAFi engagement in normal tissues, oversuppressing MAPK signaling and limiting the therapeutic index. RAF/MEK glues constitute a distinct category of MEK inhibitors that stabilize RAF-MEK complexes and functionally suppress RAF. Although structural studies have captured these glues bound to both active and inactive RAF conformations, we show that their inhibitory activity stems from a spatial-trapping mechanism: we found that MEK is constitutively cytosolic, RAF/MEK glues sequester RAF in the cytosol, blocking its membrane recruitment and dimerization, steps essential for activation. In line with this mechanism, the RAF/MEK glue avutometinib, when combined with a pan-RAFi, was well tolerated at full dose and, critically, drove tumor regressions across multiple RAS-MUT models, achieving a 90% ORR compared with 0% using a conventional pan-RAFi + MEKi regimen in an insensitive RAS-MUT model. Tumor regressions corresponded with deeper MAPK pathway suppression by both pharmacodynamic and transcriptional metrics, without increased toxicity. Together, these findings reveal an unrecognized mechanism of RAF inactivation by RAF/MEK glues and show that substituting the MEKi with a RAF/MEK glue can overcome the therapeutic ceiling of current MAPK-targeting regimens, shifting outcomes from mostly stable disease to frequent tumor regressions. More broadly, this work establishes drug-induced proximity as a means to increase tumor selectivity by reprogramming the spatial and biochemical state of wild-type signaling effectors, thereby widening the therapeutic window for oncogenic pathway inhibition and providing a new paradigm for precision oncology. Citation Format: Bijaya Gaire, Ana Orive-Ramos, Christos Adamopoulos, Beau Baars, Mathieu Desaunay, Evangelia Matenoglou, Silvia Coma, Nayeli Gutierrez-Trejo, Kevin Mohammed, Stuart A. Aaronson, Jian Jin, Tiphaine Martin, Ernesto Guccione, Evripidis Gavathiotis, Jonathan A. Pachter, Poulikos I. Poulikakos. A spatial-trapping mechanism of RAF by RAF/MEK glue enables full-dose combination with a pan-RAF inhibitor and drives potent, RAS-mutant tumor-selective MAPK and growth inhibition [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2948.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ESTHERDY完成签到,获得积分10
1秒前
3秒前
xzlijingjing完成签到 ,获得积分10
3秒前
王亚娟完成签到,获得积分10
3秒前
乐乐的应助被苏小咩采纳,获得10
3秒前
4秒前
宇明发布了新的文献求助10
4秒前
催化剂完成签到,获得积分10
4秒前
ESTHERDY发布了新的文献求助20
5秒前
kkkkkkk完成签到 ,获得积分10
5秒前
勒言发布了新的文献求助10
5秒前
啊啊啊啊完成签到 ,获得积分10
6秒前
7秒前
卿云完成签到 ,获得积分10
8秒前
8秒前
华仔的应助被勒言采纳,获得10
9秒前
9秒前
赘婿的应助被王禹垚采纳,获得10
10秒前
rururu发布了新的文献求助10
10秒前
11秒前
上官若男的应助被lyj采纳,获得10
12秒前
will_li完成签到,获得积分10
12秒前
香蕉觅云的应助被阿盛采纳,获得10
13秒前
田様的应助被孙浩文采纳,获得10
13秒前
13秒前
Tsjng完成签到,获得积分10
13秒前
13秒前
国服躺赢发布了新的文献求助30
14秒前
顺其自然完成签到,获得积分10
15秒前
李瑞程发布了新的文献求助10
15秒前
16秒前
16秒前
松鹤问道完成签到 ,获得积分10
17秒前
17秒前
彩色鸿涛发布了新的文献求助10
18秒前
My_magnum_opus的应助被林夕采纳,获得30
18秒前
jjdgangan完成签到,获得积分10
19秒前
Jio-PPx发布了新的文献求助10
19秒前
heyi1217发布了新的文献求助10
20秒前
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183263
求助须知:如何正确求助?哪些是违规求助? 9572532
关于积分的说明 21826339
捐赠科研通 7780187
什么是DOI,文献DOI怎么找? 3433993
关于科研通互助平台的介绍 2558131
邀请新用户注册赠送积分活动 2480239